Solid & liquid biopsy
- 1 block or 25 slides
- 2 blood samples
10 working days
Scroll down to discover
This solution is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples).
OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, chemotherapies and immunotherapies.
Solid and liquid biopsy
313 genes for the solid biopsy
Number of genes for the liquid biopsy variable depending on the cancer type
10 working days
For 92% of the oncologists, combining NGS with Package Plus* has a better clinical insight.
*Package plus includes additional test of imunohistochemistry (IHC) for chemo, immuno and targeted therapies, and other molecular test like: methylation of the MGMT promoter, the expression of either EGFRVIII, MET protein, receptor tyrosine kinase (MET)- exon 14 deletion or androgen-receptor splice variant 7 (ARV7), and microsatellite instability testing. (Laes et al 2018)
92.7% of the oncologists agreed with OncoDNA’s recommendations.
(Laes et al 2018)
DNA, RNA and protein changes approach in tumors: cases for which OncoDNA recommendations were followed, at least 50% of the patients had an OS of > 6 months, and 27% of patients had a minimum overall survival > 12 months (expected OS of ~3 -6 months) (Laes et al 2018)
Our immunogram is created based on 5 key points, PD-L1 % (FDA) , TMB (ASCO 2017) (12), CD8 T-cell infiltrate (ASCO 2017), MSI(FDA) and Sensitivity/Resistance mutations (ASCO 2017)(13). With those tools, we are able to give you a clear vision of the potential clinical response of your patient.
OncoDNA publishes regularly in peer-reviewed international journals.
Here below you will find a selection of key publications supporting the clinical evidences of OncoSTRAT&GO.
Male, 70 years old
We found an EGFR L858R mutation. This is one of the most frequent EGFR mutations in NSCLC (26-40%) and the most common sensitizing mutation to EGFR-TKI therapies, it has been reported to double the phosphorylation effects of EGFR after ligand treatment. NSCLC patients carrying this mutation are responsive to gefitinib and erlotinib therapies. Based on package plus analysis, this patient should be sensitive to gemcitabine based chemotherapy. On the other hand this patient should not be sensitive to taxane, 5-FU based chemotherapies and to ALK/RET/ROS1/NTRK, MET, PI3K and dual PI3K/mTOR inhibitor.
Male, 58 years old
SOLID PART: We found a BRCA2 stop codon. BRCA2 loss of function mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. PARP inhibitors attack tumours defective in the BRCA2 gene by a concept termed ‘synthetic lethality’. If a BRCA2 mutation is present, the breast cancer is less likely to be oestrogen-receptor-positive, which means that the patient may not be a candidate for treatment with hormonal therapy. Several PARP inhibitors are recommended by NCCN guidelines and FDA approved for the treatment of breast cancer HER2-negative, BRCA1/2 positive. Based on package plus analysis, this patient should be sensitive to ER, CDK4/6 inhibitors. On the other hand this patient should not be sensitive to 5-FU based chemotherapy and to HER2, PI3K, dual PI3K/mTOR inhibitors.
LIQUID PART: The hereditary germline cancer panel has been performed on the peripheral blood mononuclear cells. A BRCA2 variant at a frequency of 51% has been found.
A comprehensive and integrated report will be available trhough the OncoSHARE platform. After 7 to 10 days, depending on the test you purchased, the analysis report will be available. In a simple and interactive manner, it will guide you in selecting the most appropriate treatment based on the unique signature of the tumor.
For more information about the price in your country please contact the sales department at sales@oncodna.com
If your question is not addressed above and/or if you would like more information about our solutions, please contact us at infos@oncodna.com our Patient and Scientific Support teams are available to answer your questions directly from Monday to Friday. You can also reach us through the chat (icon in the bottom right corner of the window).
OncoDEEP analyses solid biopsies by combining nextgeneration sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it also includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in literature in order to provide patients with the most cost-effective solution.
Read more
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.
Read more
OncoTRACE by OncoDNA is a test based on circulating tumor DNA (ctDNA) in liquid biopsies (principally blood). It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customized for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.
In 2013 OncoDNA became the first company to personalise a specific OncoTRACE test for every patient (a recent publication in 2017 in Nature demonstrates the efficacy of such an approach). Chrisie et al Journal of Clinical Oncology 35, no. 12 (April 20, 2017) 1274-1280.
Read more
